V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10412348 | 10041174 | 0.9 | 89.7 | Palliative (P) | 2021-04-28 | 2021-04-29 | CARBOPLATIN + VINORELBINE | 02 | N | CARBOPLATIN + VINORELBINE | 100460271 |
| 10412385 | 10041175 | null | 69 | Curative (C) | 2017-12-05 | 2017-12-05 | CVP R | 02 | null | CVP R | 100680448 |
| 10412394 | 10041176 | 1.69 | 63.1 | Adjuvant (A) | 2017-11-07 | 2017-11-13 | Acalabrutinib | N | N | ACALABRUTINIB | 100190269 |
| 10412427 | 10041177 | 1.78 | 47 | Adjuvant (A) | 2019-05-07 | 2019-05-07 | CARBOPLATIN + VINORELBINE | 02 | N | CARBOPLATIN + VINORELBINE | 101751325 |
| 10412516 | 10041178 | 1.79 | 70 | Palliative (P) | 2019-08-29 | 2019-09-05 | Nilotinib | 02 | N | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 101339286 |
| 10412690 | 10041180 | 1.73 | 79.2 | null | 2021-10-28 | 2021-11-15 | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 02 | null | ABEMACICLIB + FULVESTRANT | 100651306 |
| 10412725 | 10041181 | 1.6 | 74.5 | Palliative (P) | 2018-12-10 | 2018-12-20 | CARBOPLATIN + GEMCITABINE + RITUXIMAB | N | null | BLEOMYCIN | 101571179 |
| 10412788 | 10041182 | 1.76 | 82.1 | Palliative (P) | 2021-10-25 | 2021-10-26 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | N | null | CISPLATIN + GEMCITABINE + RITUXIMAB | 100138088 |
| 10412812 | 10041183 | null | 58 | Palliative (P) | 2017-05-22 | 2017-06-18 | DA 3 + 10 | N | N | SCOPE 1 TRIAL | 100664219 |
| 10412813 | 10041184 | 1.83 | 85.3 | Curative (C) | null | 2018-02-20 | AVELUMAB + AXITINIB | N | y | DOXORUBICIN EMBOLISATION | 101402022 |
| 10413023 | 10041186 | 1.8 | 77.3 | Curative (C) | 2019-05-24 | 2019-06-02 | Cisplatin + Etoposide po&iv 3 day | 02 | null | STAMPEDE TRIAL | 100528365 |
| 10413092 | 10041187 | 1.73 | 0 | Palliative (P) | 2015-04-02 | 2018-11-22 | null | N | N | CRIZOTINIB | 100338791 |
| 10413115 | 10041188 | 1.74 | 80.7 | Disease modification (D) | 2017-11-29 | 2017-12-06 | FLUOROURACIL + OXALIPLATIN + PANITUMUMAB | N | Y | FCR | 100287870 |
| 10413178 | 10041190 | 1.7 | 71.7 | Disease modification (D) | 2017-12-06 | 2017-12-18 | Ixazomib + Lenalidomide | 02 | N | ABEMACICLIB + FULVESTRANT | 100155341 |
| 10413215 | 10041191 | 1.78 | 52.1 | Neo-adjuvant (N) | 2016-02-01 | 2018-05-05 | Dasatinib | null | N | CISPLATIN + GEMCITABINE + RITUXIMAB | 100986317 |
| 10413486 | 10041193 | 1.64 | 67.3 | null | 2018-12-23 | 2019-01-09 | Obinutuzumab + Venetoclax | 02 | N | STAMPEDE TRIAL | 100692375 |
| 10413529 | 10041194 | 1.46 | 60.9 | Palliative (P) | 2019-01-18 | 2019-02-05 | Carboplatin + Liposomal Doxorubicin | 02 | N | GEFITINIB | 101550797 |
| 10413687 | 10041197 | 1.8 | 69.5 | Palliative (P) | 2018-03-18 | 2018-03-25 | Radium 223 | 02 | N | APALUTAMIDE | 100195857 |
| 10413761 | 10041199 | 1.73 | 60.6 | Palliative (P) | 2018-11-14 | 2018-11-16 | Melphalan IV High dose | null | N | ENRICH TRIAL | 101141942 |
| 10413791 | 10041202 | 1.7 | 50 | Disease modification (D) | 2019-01-01 | 2019-01-17 | Capecitabine (21days) + Carboplatin | N | N | APALUTAMIDE | 100921426 |
| 10413859 | 10041204 | 1.65 | 78.2 | Palliative (P) | 2021-10-08 | 2021-10-10 | null | 01 | N | ETOPOSIDE | 100424949 |
| 10414011 | 10041206 | 1.68 | 83.4 | Palliative (P) | 2016-07-09 | 2016-07-09 | LANREOTIDE | 02 | null | ATEZOLIZUMAB | 100009725 |
| 10414044 | 10041207 | 1.62 | 77.6 | Adjuvant (A) | 2017-12-28 | 2018-01-04 | Bortezomib + Daratumumab | N | N | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101077913 |
| 10414077 | 10041208 | 1.83 | 61.3 | Curative (C) | 2019-07-13 | 2019-07-21 | AVELUMAB + AXITINIB | null | N | DOXORUBICIN EMBOLISATION | 101768629 |
| 10414088 | 10041210 | null | 74.7 | null | 2019-04-06 | 2019-04-23 | OSIMERTINIB | 02 | null | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 101747330 |
| 10414125 | 10041211 | 0 | null | 03 | null | 2018-04-04 | null | Y | null | LETROZOLE + PALBOCICLIB | 101416885 |
| 10414433 | 10041213 | 1.52 | 79.6 | Palliative (P) | 2018-03-25 | 2018-03-25 | FCR Oral - Cycle 1 | Y | N | BEXAROTENE | 100008163 |
| 10414556 | 10041215 | 1.78 | 53.2 | 03 | 2012-06-24 | 2017-03-27 | CISPLATIN + RT | 02 | null | BEXAROTENE | 100159373 |
| 10414649 | 10041216 | 1.71 | 89.3 | 03 | 2017-09-08 | 2017-09-08 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | 02 | N | CISPLATIN + PEMETREXED | 101740330 |
| 10414656 | 10041217 | 1.73 | 62.3 | Palliative (P) | 2019-05-17 | 2019-05-17 | FURVA Trial | 02 | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 101015032 |
| 10414738 | 10041218 | 1.8 | 70.4 | Palliative (P) | 2015-01-11 | 2015-01-26 | Raltitrexed | 02 | N | CABOZANTINIB | 100011192 |
| 10415021 | 10041220 | 1.76 | 65.6 | null | 2019-11-07 | 2019-11-20 | Letrozole + Palbociclib | N | N | CAPECITABINE + CARBOPLATIN | 101060188 |
| 10415041 | 10041221 | 0.64 | 110.9 | Neo-adjuvant (N) | 2017-07-25 | 2017-07-25 | CHLVPP | 02 | N | DOXORUBICIN | 101452107 |
| 10415123 | 10041222 | 1.5 | 66 | 03 | 2020-01-25 | 2020-02-07 | Capecitabine+Cisplatin+Streptozocin | 02 | N | FEC + DOCETAXEL | 100217315 |
| 10415124 | 10041223 | 1.71 | 62 | Curative (C) | 2019-06-22 | 2019-06-24 | Temozolomide + RT | 02 | N | IXAZOMIB + LENALIDOMIDE | 101321236 |
| 10415125 | 10041224 | 1.5 | 39 | Palliative (P) | 2016-06-26 | 2016-06-27 | Bortezomib + MELPHALAN | 02 | N | FEC | 101037935 |
| 10415340 | 10041225 | 1.58 | 94 | Palliative (P) | null | 2017-12-22 | TALIMOGENE LAHERPAREPVEC | N | N | INTERLACE TRIAL | 100368755 |
| 10415538 | 10041226 | 1.69 | 82.1 | Curative (C) | 2019-06-12 | 2019-06-30 | Bexarotene | 02 | N | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 100726910 |
| 10415591 | 10041228 | 1.84 | null | Curative (C) | 2019-04-23 | 2019-04-25 | AML 18 TRIAL | 02 | N | PEG INTERFERON ALFA | 101841788 |
| 10415633 | 10041230 | 0 | 63.7 | Disease modification (D) | null | 2018-01-24 | CISPLATIN + EPIRUBICIN + FLUOROURACIL | 2 | N | IXAZOMIB + LENALIDOMIDE | 101175266 |
| 10415757 | 10041231 | null | null | Curative (C) | 2015-09-08 | 2015-09-23 | Doxorubicin 75mg/m2 | 02 | N | ECX | 100657848 |
| 10415856 | 10041234 | 1.76 | 93.3 | null | null | 2020-06-29 | MaxiCHOP (Cycle 1) | N | N | THALIDOMIDE | 101703158 |
| 10415900 | 10041235 | 1.55 | 53.15 | Adjuvant (A) | null | 2020-03-25 | FEC + TRASTUZUMAB | N | null | DOXORUBICIN EMBOLISATION | 101412971 |
| 10416056 | 10041237 | 1.58 | 72.5 | Palliative (P) | 2018-11-21 | 2018-11-23 | ANAGRELIDE | 02 | N | ANAGRELIDE | 101496031 |
| 10416063 | 10041238 | 1.87 | 70.9 | Curative (C) | 2020-01-27 | 2020-01-27 | EOX | 02 | N | BINIMETINIB + ENCORAFENIB | 101234752 |
| 10416131 | 10041240 | 1.6 | 0 | Adjuvant (A) | 2017-11-21 | 2017-11-22 | DOXORUBICIN | null | N | BORTEZOMIB + DARATUMUMAB + THALIDOMIDE | 100795661 |
| 10416224 | 10041242 | 1.77 | 65.2 | null | 2021-03-18 | 2021-03-25 | GemCarbo Days 1+8 | 02 | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 100714704 |
| 10416232 | 10041243 | 1.73 | 91 | 03 | 2018-12-13 | 2018-12-18 | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 02 | null | GDP | 100742902 |
| 10416233 | 10041244 | 0 | 56.25 | Palliative (P) | 2018-08-20 | 2018-09-06 | OSIMERTINIB | 02 | N | VINORELBINE | 100355485 |
| 10416414 | 10041248 | 1.52 | 70 | null | 2018-10-18 | 2018-11-05 | Liposomal Doxorubicin (Caelyx) | 02 | null | BLEOMYCIN | 101065121 |